All news

24 October 2026

Amgen's lung cancer drug added eight months of median survival in a big trial

Adding Amgen's Imdelltra to AstraZeneca's Imfinzi cut the risk of death by 58% in advanced small cell lung cancer, full late-stage trial results show.

Small cell lung cancer is one of the fastest-moving cancers there is. Chemotherapy often works at first, then the disease comes back within months. On Saturday Amgen released full results from a late-stage trial suggesting its drug Imdelltra can buy patients a lot more time.

What happened

The trial looked at patients with extensive-stage disease, meaning the cancer had already spread beyond the lung. All had first been treated with chemotherapy plus Imfinzi, an immunotherapy from AstraZeneca, and their cancer had not grown since. They then got either Imfinzi alone or Imfinzi plus Imdelltra as maintenance therapy, the ongoing treatment given after the heavy first round.

  • Risk of death fell by 58% with the combination.
  • Median overall survival (the point by which half the patients had died) rose to 21.1 months from 12.7 months.
  • Nearly 80% of combination patients were alive after a year, versus 53% on Imfinzi alone.
  • The benefit held in patients whose cancer had reached the brain or liver, groups that usually do worse.

The two drugs work in different ways. Imfinzi takes the brakes off the immune system. Imdelltra grabs a protein on tumor cells and a protein on T cells, the immune cells that kill cancer, and pulls the two together. Amgen's chief medical officer, Paul Burton, called it a moment that could "transform the standard of care."

The results were presented at the European Society for Medical Oncology Congress, a major cancer meeting. One limit: the study did not compare the combination with other first-line approaches, only with Imfinzi alone.

Why it matters

Today Imdelltra is approved only for patients whose cancer has worsened during or after platinum-based chemotherapy. Moving it earlier in treatment would put it in front of many more people. There are about 31,000 new small cell lung cancer cases a year in the US, and 60% to 70% are diagnosed at the extensive stage.

The drug is already growing fast. It sold $627 million in 2025 and $288 million in the second quarter of 2026 alone, up 115% from a year earlier. A drug that sells $1 billion a year earns the industry label blockbuster, and Imdelltra is heading that way. For scale, Amgen brought in about $38 billion of revenue over the last twelve months, according to its filings on Noorult, so one drug is still a small slice of a very large company.

What to watch

  • Whether Amgen files with regulators to use Imdelltra as a first-line maintenance treatment.
  • Longer follow-up data, which researchers hope will push the 21-month figure higher.
  • Imdelltra's quarterly sales as Amgen reports earnings.

Amgen's full financials are on its Noorult company page, and AstraZeneca's are on its page.

The companies in this story

Based on reporting by CNBC: Amgen's Imdelltra combo cuts risk of death by 58% in lung cancer. Facts, not advice.

More news